3 Stocks Pushing The Health Care Sector Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 108 points (0.7%) at 16,372 as of Friday, March 28, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,438 issues advancing vs. 544 declining with 153 unchanged.

The Health Care sector currently sits up 0.1% versus the S&P 500, which is up 0.8%. On the negative front, top decliners within the sector include Gilead ( GILD), down 3.1%, and Biogen Idec ( BIIB), down 1.3%. Top gainers within the sector include Smith & Nephew ( SNN), up 2.4%, WellPoint ( WLP), up 2.4%, Intuitive Surgical ( ISRG), up 2.2%, HCA Holdings ( HCA), up 2.2% and Valeant Pharmaceuticals International ( VRX), up 2.1%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Biomarin Pharmaceutical ( BMRN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biomarin Pharmaceutical is down $1.80 (-2.6%) to $67.11 on average volume. Thus far, 737,882 shares of Biomarin Pharmaceutical exchanged hands as compared to its average daily volume of 1.4 million shares. The stock has ranged in price between $66.68-$69.69 after having opened the day at $69.38 as compared to the previous trading day's close of $68.91.

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Biomarin Pharmaceutical has a market cap of $10.1 billion and is part of the drugs industry. Shares are down 2.0% year-to-date as of the close of trading on Thursday. Currently there are 11 analysts that rate Biomarin Pharmaceutical a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Biomarin Pharmaceutical as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. Get the full Biomarin Pharmaceutical Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $1.47 (-2.1%) to $69.31 on light volume. Thus far, 470,372 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $68.99-$72.67 after having opened the day at $71.07 as compared to the previous trading day's close of $70.78.

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $16.6 billion and is part of the drugs industry. Shares are down 4.7% year-to-date as of the close of trading on Thursday. Currently there are 14 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income and revenue growth. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and feeble growth in the company's earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Regeneron Pharmaceuticals ( REGN) is down $5.58 (-1.8%) to $306.28 on average volume. Thus far, 587,532 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $305.01-$316.00 after having opened the day at $313.11 as compared to the previous trading day's close of $311.86.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $30.2 billion and is part of the drugs industry. Shares are up 13.3% year-to-date as of the close of trading on Thursday. Currently there are 9 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Starbucks Surprises With U.S. Sales Up 2%

Starbucks Surprises With U.S. Sales Up 2%

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Dow Jumps 238 Points as S&P 500, Nasdaq Also Climb

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

Why Nashville, Denver, LA Should Reconsider Bids for Amazon HQ2

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company

Jim Cramer: Visa Is a Technology Company That Masquerades as a Financial Company